BRUSSELS - The European Commission said on Wednesday it had sealed a deal with US pharmaceutical giant Pfizer and German company BioNTech for the supply of up to 300 million doses of their COVID-19 vaccine candidate.
Under the EU deal, the 27 EU countries could buy 200 million doses, and have an option to purchase another 100 million.
The move follows Pfizer’s announcement on Monday that its experimental vaccine developed with BioNTech was more than 90 percent effective, making them the first drugmakers to show successful interim data from a large...
The article you requested can be accessed only by subscribing to the online version of The Baltic Times. If you are already subscribed to The Baltic Times, please authorize yourself.
In case you don't have a subscription yet - please visit our SUBSCRIPTION